Research
Hormonal
The typical hormonal environment in fatty liver disease—hyperinsulinemia, hyperglucagonemia, hypercortisolemia, and growth hormone deficiency—synergistically encourages further hepatic steatosis by dysregulating adipose lipolysis and hepatic lipid handling.
Your body's hormone levels (insulin, cortisol, glucagon) are not just bystanders in fatty liver; they actively drive more fat into the liver. Addressing insulin resistance and stress is key to breaking this cycle.
GoodSupportsHIGH confidence
The typical hormonal environment in fatty liver disease consists of hyperinsulinemia, hyperglucagonemia, hypercortisolemia, growth hormone deficiency, and elevated sympathetic tone. These endocrine and metabolic changes further encourage hepatic steatosis by regulating adipose tissue lipolysis, liver lipid uptake, de novo lipogenesis (DNL), beta-oxidation, ketogenesis, and lipid export.
Why this rating
Supported by extensive clinical data on hormonal profiles in NAFLD patients cited in the review.
Source
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones
Caroline E. Geisler et al. · Journal of Endocrinology · 2017
DOI 10.1530/joe-16-0513
narrative_reviewCited 194×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Hepatic lipid accumulation acts as a primary driver of systemic metabolic dysfunction by serving as ligands for PPARs, which upregulate gluconeogenic, lipogenic, and ketogenic genes, thereby promoting hyperglycemia and hyperlipidemia.Good
- Fructose consumption promotes hepatic de novo lipogenesis (DNL) and NAFLD development through both substrate provision and independent upregulation of lipogenic transcription factors (SREBP1c and ChREBP), even in the absence of insulin signaling.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →